Mahmud, Sarwat; Kouyoumjian, Silva P; Al Kanaani, Zaina; Chemaitelly, Hiam; Abu-Raddad, Laith J; (2018) Individual-level key associations and modes of exposure for hepatitis C virus infection in the Middle East and North Africa: a systematic synthesis. ANNALS OF EPIDEMIOLOGY, 28 (7). pp. 452-461. ISSN 1047-2797 DOI: https://doi.org/10.1016/j.annepidem.2018.03.007

Downloaded from: http://researchonline.lshtm.ac.uk/4652209/

DOI: https://doi.org/10.1016/j.annepidem.2018.03.007

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Original article

Individual-level key associations and modes of exposure for hepatitis C virus infection in the Middle East and North Africa: a systematic synthesis

Sarwat Mahmud, MPH a, Silva P. Kouyoumjian, MSc a, Zaina Al Kanaani, PhD a, Hiam Chemaitelly, MSc a, Laith J. Abu-Raddad, PhD a, b, *

A series of systematic reviews and meta-analyses were conducted recently to characterize HCV epidemiology in MENA [5–14]. Varying HCV prevalence in the general population was observed across MENA countries. Countries with the highest HCV prevalence were Egypt at 11.9% [6] and Pakistan at 6.2% [14]. For the remaining countries, HCV prevalence was comparable to global levels, ranging from 0.2% in Iraq, Lebanon, and Palestine [9], to 1.9% in Yemen [10]. HCV genotype distribution and its regional trends were also delineated [15,16]. HCV viremic rate, that is, the proportion of HCV chronically infected individuals of all ever-infected individuals, was also recently assessed [17]. Two-thirds of HCV antibody-positive individuals in MENA were found chronically infected and in need of treatment [17]. The systematic reviews conducted quality assessments of included HCV studies, and existing evidence was found to be of reasonable quality [5–14]. The diagnostic tests used

https://doi.org/10.1016/j.annepidem.2018.03.007

*Corresponding author. Infectious Disease Epidemiology Group, Weill Cornell Medicine - Qatar, Qatar Foundation - Education City, Doha, Qatar. Tel.: + (974) 4492-8321; fax: + (974) 4492-8333.
E-mail address: lj2002@qatar-med.cornell.edu (L.J. Abu-Raddad).

© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
were also overall of quality, with most studies using the more sensitive and specific third- or fourth-generation assays for HCV antibody detection, with many studies using confirmatory tests also [5–14].

The recent development of the highly efficacious direct-acting antivirals provides avenues for achieving major reductions in HCV infection and disease burden [18,19]. As such, a global target has been set to eliminate HCV as a public health concern by 2030 [20,21]. However, screening those chronically infected and ensuring access to treatment remain major challenges across MENA [22,23]. Prevention of new HCV infections is also integral to achieving elimination by 2030 [21].

The key associations and modes of exposures for HCV infection vary across regions and countries [24–26]. For example, health care–related exposures appears to be an important mode of exposure in low- and middle-income countries; however, it is no longer a major mode of exposure in many developed countries [24–26]—such as the United States where most exposures appear to be related to injecting drug use [26,27]. This highlights the need to identify, for each region or country, the specific modes of exposures for HCV infection to inform HCV response and progress toward HCV elimination by 2030.

Against this background, the specific aim of our study is to delineate and map, through comprehensive systematic searches of HCV literature in MENA, the individual-level key associations and modes of exposure for HCV infection. The overarching goals of our study are to inform HCV prevention by identifying the modes of exposures and settings of vulnerability for this infection and to inform the development of cost-effective screening strategies that can identify infected individuals with a high yield. To our knowledge, this is the first systematic synthesis for any world region of HCV key associations and modes of exposure.

This work was conducted as part of the MENA HCV Epidemiology Synthesis Project—an ongoing effort to describe and understand HCV epidemiology in MENA and to inform key public health research, resource allocation, policy, and programming priorities in the region [5–15,17,28–31].

Methods

Data sources

The source of data for our study was the MENA HCV Epidemiology Synthesis Project database, a comprehensive database of HCV epidemiological measures in MENA [5–14]. The database consists of several subdatabases of studies for different outcomes, such as HCV antibody prevalence subdatabase comprised of 2543 antibody prevalence studies among 51,998,736 participants, ribonucleic acid prevalence (among antibody-positive persons) subdatabase comprised of 178 ribonucleic acid prevalence studies among 19,593 HCV antibody-positive participants, and genotype frequency subdatabase comprised of 338 HCV genotype studies among 82,257 participants. The database also includes a subdatabase of individual-level HCV risk factors including 329 risk factors identified from 109 studies. The latter subdatabase is the focus of our analyses in the present article. The MENA HCV Epidemiology Synthesis Project database was constructed through a series of systematic reviews for HCV infection across MENA [5–14].

Systematic reviews: overview

The systematic reviews were informed by the Cochrane Collaboration Handbook [32] and reported their findings using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines [33]. The Preferred Reporting Items for Systematic Reviews and Meta-analyses flow diagrams describing the selection process by which studies were included can be found in the respective systematic reviews [5–14]. Reviewed evidence included peer-reviewed publications identified through international scientific databases (PubMed and Embase), regional- and country-level scientific databases, MENA HIV/AIDS Epidemiology Synthesis Project database [34,35], abstract archives of nonindexed international conferences, and gray literature comprised of public health reports and routine data reporting.

Broad search criteria were used in these reviews combining medical index terms exploded to cover all subheadings and free text terms for HCV and country names, to ensure inclusiveness. No language restrictions were used as non-English articles were extracted by native speakers. Screening of articles was restricted to those published after 1989, the year in which HCV was identified as a virus for the first time [36,37].

Inclusion and exclusion criteria

The systematic reviews used the same inclusion and exclusion criteria adapted for the subregion or country of interest [5–14]. The specific inclusion and exclusion criteria can be found in detail in the respective systematic reviews [5–14]. Briefly, all studies included in the reviews qualified for inclusion if they reported HCV antibody incidence and/or antibody prevalence based on biological assays and on primary data, in any population, in Afghanistan, Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, the United Arab Emirates, or Yemen. Studies had to have a minimum sample size of 25. The exclusion criteria encompassed case reports, case series, editorials, letters to editors, commentaries, literature reviews, and studies reporting HCV prevalence based on self-reporting. Studies referring to HCV as non-A non-B hepatitis, or were performed before 1989, were also excluded.

Extraction of risk factors and conceptual mapping

These systematic searches identified studies that assessed individual-level risk factors for incident HCV infection (in prospective or retrospective incidence studies) or individual-level factors associated with being infected with HCV infection (in cross-sectional studies of prevalent HCV infections). While these two types of factors are technically different and have been derived using different epidemiologic study designs, our focus in the present study is to identify factors that are predictive of HCV infection, whether they are potentially causal factors (such as injecting drug use or blood transfusion) or just reflect associations with HCV infection (such as age or socioeconomic status).

We extracted from the retrieved articles of the systematic searches only risk factors determined to be statistically significant through multivariable regression analyses—that is, after controlling for potential confounding factors. These risk factors were subsequently used to populate the HCV risk factors subdatabase indicated previously.

The extracted risk factors were classified into two categories: key associations and modes of exposure. A key association was defined as a characteristic associated with being infected with HCV (such as age or socioeconomic status), but is not a mode of exposure (or transmission). A mode of exposure was defined as an exposure factor that was potentially responsible for acquiring HCV infection (such as injecting drug use or blood transfusion). Conceptual maps by type of risk factors were developed based on the identified risk factors in the systematic searches.
Table 1
Number of articles reporting individual-level risk factors for incident HCV infection (in prospective or retrospective incidence studies) or individual-level factors associated with being infected with HCV infection (in cross-sectional studies of prevalent HCV infections) in the Middle East and North Africa (MENA)

<table>
<thead>
<tr>
<th>Country</th>
<th>Number of articles reporting risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Egypt</td>
<td>53</td>
</tr>
<tr>
<td>Iran</td>
<td>26</td>
</tr>
<tr>
<td>Pakistan</td>
<td>11</td>
</tr>
<tr>
<td>Iraq</td>
<td>3</td>
</tr>
<tr>
<td>Libya</td>
<td>3</td>
</tr>
<tr>
<td>Morocco</td>
<td>2</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>2</td>
</tr>
<tr>
<td>Tunisia</td>
<td>2</td>
</tr>
<tr>
<td>Yemen</td>
<td>2</td>
</tr>
<tr>
<td>Afghanistan</td>
<td>1</td>
</tr>
<tr>
<td>Kuwait</td>
<td>1</td>
</tr>
<tr>
<td>Qatar</td>
<td>1</td>
</tr>
<tr>
<td>Sudan</td>
<td>1</td>
</tr>
<tr>
<td>Syria</td>
<td>1</td>
</tr>
<tr>
<td>Middle East and North Africa</td>
<td>109</td>
</tr>
</tbody>
</table>

All reported risk factors that met the definition of a key association were included in the conceptual map for the key associations. Similarly, all reported risk factors that met the definition of a mode of exposure were included in the conceptual map for the modes of exposure, and were further categorized into health care–related exposures, injecting drug use–related exposures, community-related exposures, and sexual-related exposures, based on the type of risk factor.

Results

Scope of evidence

Table 1 lists (by country) the number of articles reporting statistically significant risk factors after adjustment for confounders. Risk factor data were available for 14 of the 24 MENA countries, 11 of which had less than five articles reporting risk factor information. Egypt had the largest number of articles \( (n = 53) \), followed by Iran \( (n = 26) \) and Pakistan \( (n = 11) \). In the 109 articles reporting risk factors, a total of 329 risk factors were identified.

Conceptual mapping of risk factors

Figure 1 provides a conceptual mapping of the key associations with HCV infection as discerned from the extracted risk factors. Diverse associations have been identified that range from basic sociodemographic attributes, to occupational or incarceration contexts, to other infection or disease status conditions.

Figure 2 provides a conceptual mapping of HCV modes of exposure as discerned from the extracted risk factors. Three main settings of exposure have been identified for HCV infection in MENA: health care–related exposures, exposures related to injecting drug use, and community-related exposures. A fourth setting, although limited in extent, was also identified: sexual exposures. Within each of these settings, different specific modes of exposure to HCV infection or associated factors were identified.

Key associations

Table 2 reports the frequency of reported key associations in MENA. A total of 114 key associations were reported, that is, 34.7% of all occasions in which a risk factor was reported.

Age was by far the most reported key association—it was reported in 39 studies, comprising 34.2% of all occasions in which a key association was reported. Following age was the category of other infections or diseases—it was reported in 20 studies, comprising 17.5% of occasions. This category included conditions such as diabetes, malaria, jaundice, and HIV, among others. Next was the category of an incarceration context—it was reported in 17 studies, comprising 14.9% of occasions. Other notable reported key associations included: sex, education, marital status, socio-economic status, rural versus urban location, and specific geographical regions.

Modes of exposure

Table 3 reports the frequency of reported modes of exposure in MENA, comprising 65.3% of all reported risk factors.
Health care–related exposures

HCV infection was often associated with health care–related exposures, comprising over half of the reported modes of exposure (59.5%). Blood transfusion was the most commonly reported mode of exposure—it was reported in 32 studies comprising 14.9% of occasions in which a mode of exposure was reported. Parenteral antischistosomal therapy (PAT) was second (24 studies; 11.2% of occasions) and all of these studies were strictly from Egypt. Hemodialysis was next, where it was reported in 21 studies, comprising 9.8% of occasions. This was followed by surgical and other medical procedures (16 studies; 7.4% of occasions), dental work (10 studies; 4.7% of occasions), and medical injections (9 studies; 4.2% of occasions). Other notable health care–related exposures included: health care worker–related exposures, hospitalization, and obstetrical care.

Exposures related to injecting drug use

Exposures (and associated factors) related to injecting drug use comprised 20.9% of all reported modes of exposure. History of injecting drug use was the most commonly reported factor (17 studies; 7.9% of occasions), followed by sharing of needles or syringes (11 studies; 5.1% of occasions), and duration of injecting drug use (6 studies; 2.8% of occasions).

Community-related exposures

Community-related exposures comprised 15.8% of all reported modes of exposure. Tattooing was the most commonly reported risk factor (10 studies; 4.7% of occasions), followed by household contacts of HCV-infected patients (7 studies; 3.3% of occasions), and informal health care practices, including cupping, male circumcision, and female genital mutilation (5 studies; 2.3% of occasions). Other notable community-related exposures included: mother-to-child transmission (4 studies; 1.9% of occasions), and exposures at barbershops (4 studies; 1.9% of occasions).

Sexual exposures

Sexual exposures were the least frequently reported modes of exposure (3.7%), among which, multiple sex partners (3 studies; 1.4% of occasions) was the most commonly reported risk factor.

Discussion

We presented a comprehensive mapping of HCV key associations and modes of exposure in MENA, to our knowledge the first such comprehensive and systematic analysis of the key associations and modes of exposure for any world region. Our results demonstrate that there are three key “collective clusters” of HCV exposures in MENA. The first relates to health care, which given the aforementioned results, appears to be the primary driver of prevalent (and possibly incident) infections. The second cluster relates to injecting drug use, whereas the third relates to community-related exposures. Despite some suggestive evidence for sexual-related exposures, these appear to play a minimal role. All identified modes of exposure confirm our overall understanding of HCV epidemiology—no unusual modes of exposure were identified in our study.

These results highlight the role that health care has played in the HCV epidemic in MENA, leading to this region being the most affected by HCV infection worldwide [2]. They also confirm our understanding of HCV epidemiology in this region, as delineated recently through a series of systematic reviews of HCV antibody prevalence [5–14]. Indeed, the pattern of HCV antibody prevalence in these studies mirrored closely that of the pattern of HCV risk factors, as analyzed in the present study. These findings testify to the need for expansion of HCV prevention in MENA through proper
Table 2  
Frequency of reported statistically significant key associations with hepatitis C virus (HCV) infection

<table>
<thead>
<tr>
<th>Key associations</th>
<th>Reported effect nature and direction</th>
<th>Frequency</th>
<th>Proportion of occasions in which this key association was reported</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Increased age associated with higher OR</td>
<td>39</td>
<td>34.2%</td>
<td>[38–74]</td>
</tr>
<tr>
<td>Other infections and diseases</td>
<td>Other infections and diseases associated with higher OR</td>
<td>20</td>
<td>17.5%</td>
<td>[44,51,56,61,63,70,73,75–79]</td>
</tr>
<tr>
<td>Incarceration</td>
<td>Incarceration and risk factors associated with incarceration associated with higher OR</td>
<td>17</td>
<td>14.9%</td>
<td>[40,47,54,78,80–91]</td>
</tr>
<tr>
<td>Sex</td>
<td>Male (n = 6), female (n = 2), and unspecified sex (n = 2), associated with higher OR</td>
<td>10</td>
<td>8.8%</td>
<td>[45,59,61,74,75,82,84,87,92,93]</td>
</tr>
<tr>
<td>Education</td>
<td>Less education associated with higher OR</td>
<td>6</td>
<td>5.3%</td>
<td></td>
</tr>
<tr>
<td>Marital status</td>
<td>Single, divorced, and widowed associated with higher OR</td>
<td>6</td>
<td>5.3%</td>
<td>[56,59,73,74,82,85]</td>
</tr>
<tr>
<td>Rural location</td>
<td>Rural residence associated with higher OR</td>
<td>5</td>
<td>4.4%</td>
<td>[45,56,59,94,95]</td>
</tr>
<tr>
<td>Region</td>
<td>Specific regions associated with higher OR</td>
<td>4</td>
<td>3.5%</td>
<td>[87,95,96]</td>
</tr>
<tr>
<td>Occupation</td>
<td>Specific occupations associated with higher OR</td>
<td>1</td>
<td>0.9%</td>
<td>[47,53]</td>
</tr>
<tr>
<td>Urban location</td>
<td>Urban residence associated with higher OR</td>
<td>2</td>
<td>1.8%</td>
<td></td>
</tr>
<tr>
<td>Socioeconomic status</td>
<td>Lower socioeconomic status associated with higher OR</td>
<td>2</td>
<td>1.8%</td>
<td></td>
</tr>
<tr>
<td>Homeless</td>
<td>Being homeless associated with higher OR</td>
<td>1</td>
<td>0.9%</td>
<td></td>
</tr>
<tr>
<td>Cigarette smoking</td>
<td>Cigarette smoking associated with higher OR</td>
<td>1</td>
<td>0.9%</td>
<td>[86]</td>
</tr>
<tr>
<td>Total</td>
<td>114</td>
<td>100%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

OR, odds ratio.
A key association is defined as a characteristic associated with being infected with HCV, but is not a mode of exposure (or transmission).

Table 3  
Frequency of reported statistically significant modes of exposure for hepatitis C virus (HCV) infection

<table>
<thead>
<tr>
<th>Modes of exposure broad category</th>
<th>Modes of exposure specific category</th>
<th>Number of studies reporting the mode of exposure</th>
<th>Proportion of occasions in which this mode of exposure was reported</th>
<th>Proportion of occasions in which this mode of exposure was reported within its broad category</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health care—related exposures</td>
<td>Blood transfusions</td>
<td>32</td>
<td>14.9%</td>
<td>25.0%</td>
<td>[41,45,46,50–53,55,56,58,64,66,67,69,73,79,86,91,94,97–107]</td>
</tr>
<tr>
<td></td>
<td>Parenteral antischistosomal therapy (PAT)</td>
<td>24</td>
<td>11.2%</td>
<td>18.8%</td>
<td>[43,53,55,56,59–64,67,68,70,101,102,105,108–113]</td>
</tr>
<tr>
<td></td>
<td>Hemodialysis</td>
<td>21</td>
<td>9.8%</td>
<td>16.4%</td>
<td>[41,52,77,92,100,106,107,114–125]</td>
</tr>
<tr>
<td></td>
<td>Surgical and other medical procedures</td>
<td>16</td>
<td>7.4%</td>
<td>12.5%</td>
<td>[45,46,56–58,64,69,71,77,92,93,101,103,112,126,127]</td>
</tr>
<tr>
<td></td>
<td>Dental work</td>
<td>10</td>
<td>4.7%</td>
<td>7.8%</td>
<td>[44,54,56,58,63,79,98,101,127,128]</td>
</tr>
<tr>
<td></td>
<td>Medical injections</td>
<td>9</td>
<td>4.2%</td>
<td>7.0%</td>
<td>[44,69,95,101,103,128,129]</td>
</tr>
<tr>
<td></td>
<td>Health care worker—related exposures</td>
<td>6</td>
<td>2.8%</td>
<td>4.7%</td>
<td>[41,40,56,69,130]</td>
</tr>
<tr>
<td></td>
<td>Hospitalization</td>
<td>4</td>
<td>1.9%</td>
<td>3.1%</td>
<td>[56,73,103,117]</td>
</tr>
<tr>
<td></td>
<td>Obstetrical care</td>
<td>4</td>
<td>1.9%</td>
<td>3.1%</td>
<td>[98,101,130,131]</td>
</tr>
<tr>
<td></td>
<td>Having thalassemia</td>
<td>2</td>
<td>0.9%</td>
<td>1.6%</td>
<td>[83]</td>
</tr>
<tr>
<td></td>
<td>Total within category</td>
<td>128</td>
<td>59.5%</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>Injecting drug use exposures</td>
<td>History of injecting drug use</td>
<td>17</td>
<td>7.9%</td>
<td>37.8%</td>
<td>[40,45–49,54,56,69,73,75,76,86,87,90,132]</td>
</tr>
<tr>
<td></td>
<td>Sharing needles or syringes</td>
<td>11</td>
<td>5.1%</td>
<td>24.4%</td>
<td>[38,45,56,64,81,82,84,88,91,133,134]</td>
</tr>
<tr>
<td></td>
<td>Duration of drug use</td>
<td>6</td>
<td>2.8%</td>
<td>13.3%</td>
<td>[38,78,82,94,135]</td>
</tr>
<tr>
<td></td>
<td>Frequency of injections</td>
<td>3</td>
<td>1.4%</td>
<td>6.7%</td>
<td>[38,82,91]</td>
</tr>
<tr>
<td></td>
<td>Other injecting drug use related exposures</td>
<td>8</td>
<td>3.7%</td>
<td>17.8%</td>
<td>[38,39,46,80,89,96,135]</td>
</tr>
<tr>
<td></td>
<td>Total within category</td>
<td>45</td>
<td>20.9%</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>Community-related exposures</td>
<td>Tattooing</td>
<td>10</td>
<td>4.7%</td>
<td>29.4%</td>
<td>[40,54,56,78,80,88,90,97,126]</td>
</tr>
<tr>
<td></td>
<td>Household contacts of HCV infected patients</td>
<td>7</td>
<td>3.3%</td>
<td>20.6%</td>
<td>[55,66,86,111,118,127,136]</td>
</tr>
<tr>
<td></td>
<td>Informal health care</td>
<td>5</td>
<td>2.3%</td>
<td>14.7%</td>
<td>[56,65,79,97,111]</td>
</tr>
<tr>
<td></td>
<td>At barbershop</td>
<td>4</td>
<td>1.9%</td>
<td>11.8%</td>
<td>[57,61,64,135]</td>
</tr>
<tr>
<td></td>
<td>Mother-to-child</td>
<td>4</td>
<td>1.9%</td>
<td>11.8%</td>
<td>[137–140]</td>
</tr>
<tr>
<td></td>
<td>Other community exposures</td>
<td>4</td>
<td>1.9%</td>
<td>11.8%</td>
<td>[56,75,78]</td>
</tr>
<tr>
<td></td>
<td>Total within category</td>
<td>34</td>
<td>15.8%</td>
<td>100.0</td>
<td></td>
</tr>
<tr>
<td>Sexual-related exposures</td>
<td>Multiple sex partners</td>
<td>3</td>
<td>1.4%</td>
<td>37.5%</td>
<td>[55,126,141]</td>
</tr>
<tr>
<td></td>
<td>Other sexual exposures</td>
<td>5</td>
<td>2.3%</td>
<td>62.5%</td>
<td>[46,75,96,134]</td>
</tr>
<tr>
<td></td>
<td>Total within category</td>
<td>8</td>
<td>3.7%</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>215</td>
<td>100.0%</td>
<td>100%</td>
<td></td>
</tr>
</tbody>
</table>

A mode of exposure is defined as an exposure factor that was potentially responsible for acquiring HCV infection.
and universal implementation of blood safety, injection safety, and infection control programs. They also inform the expansion of HCV screening and direct-acting antivirals treatment programs, by targeting the individual-level key associations and modes of exposure as delineated in the present study.

A main highlight of our study is that very specific health care exposures were repeatedly identified as risk factors, namely blood transfusion and hemodialysis. This may suggest that these exposures contribute more than previously thought to HCV incidence in the population, and therefore, even limited rollout of interventions focused on such specific exposures may result in substantial decline in HCV incidence. This seems to be supported by the large decline in HCV incidence observed in the United States immediately after the introduction of blood screening and other basic measures after identification of the virus [142]. National governments of resource-limited countries could focus initially on HCV prevention through blood safety and proper infection control in hemodialysis as a first step to advance the broader agenda of HCV prevention. Ultimately, although, with the evidence for a broad range of health care exposures contributing to HCV infection transmission, such as medical injections and dental work (Table 3), all different health care–related modes of exposure need to be addressed.

The role that blood transfusion plays in HCV exposures should not be surprising in context of continued concerns about blood safety in MENA [143]. Fragmented blood transfusion services, inappropriate clinical use of blood and blood products, and use of low-cost low-sensitivity screening kits have been observed in several MENA countries [143], such as in Pakistan, which has one of the largest HCV epidemics worldwide [30]. Establishing a centralized blood transfusion service, such as in Iran, may markedly improve accessibility to safe blood and blood products [143].

Similarly, the role of medical injections in HCV exposures should not be surprising given that this region has the highest rate of medical injections of all regions, at 4.3 per person per year [144,145]. A large proportion of these medical injections are administered unnecessarily, based on patients’ perception that injectable medications are more effective than other types of equally effective therapies [146,147]. It is critical for MENA countries to ensure safe injection practices and to adopt the new World Health Organization guidelines for the use of safety-engineered syringes [148–150].

Our results highlight that exposures related to injecting drug use are a main driver of HCV infection in MENA, similar to that observed globally [151]. However, unlike many developed countries such as the United States where injecting drug use is the main driver of HCV incidence [27,152], the role of this cluster of exposures appears second to that of health care in MENA. This should not distract from the fact that injecting drug use is a major source of exposures that needs to be addressed urgently with harm reduction services, given the scale of this practice in this region [153]. Although seven MENA countries have implemented needle/syringe exchange programs, their coverage remains limited, apart from Iran, where successful needle and syringe programs have been operational for over a decade [151,154].

Although less frequently, HCV transmission has been linked to unsafe practices in the community, particularly those including the use/reuse of unsterile needles/syringes and contaminated sharp objects (Table 3). Among the frequently reported community-related exposures are tattooing, engagement in informal health care practices (such as cupping, male circumcision, and female genital mutilation), and using services at a barbershop. Opportunities for reducing these exposures, or reducing the risk of exposure through them, should be explored.

Among the key associations identified in this study, age was most commonly reported. This affirms the strong association between age and HCV infection, reflecting age as a proxy for the cumulative risk of exposure, and possibly suggesting that the likelihood of exposure could be age dependent—say more encounters with health care with older age. Another key association was incarceration. Incarcerated populations may engage in various high risk behaviors (before or during incarceration), such as injecting drug use, tattooing, and unprotected anal sex [155].

Although age and incarceration were common key associations across the region, other identified key associations appear to be location-dependent reflecting the nature of the HCV epidemics in individual countries, or in subnational units of these countries. Rural residence, for example, is a risk factor for HCV infection in Egypt [5,156], but may not be so in other countries. The sex effect (male vs. female) may vary also in nature and strength across the region. This is demonstrated in Table 1 where although most studies reported an association between male sex and HCV infection, several other studies reported that but for female sex. These variations across the region extend also to some of the modes of exposure. PAT, in particular, appears to be a mode of exposure but only in Egypt, confirming the link between mass PAT campaigns and the HCV epidemic in Egypt [157,158].

This study has limitations. Although we aimed to provide a regional picture of HCV key associations and modes of exposure, there is large heterogeneity in availability of evidence. Few countries, such as Egypt and Iran, contributed multiple studies, whereas no studies were available for 10 MENA countries. This may limit the generalizability of the identified key associations and modes of exposures to countries with limited data. Relatively small number of studies were identified from Pakistan (only 11), although Pakistan is enduring a large epidemic with an HCV antibody prevalence of about 5% and over six million chronically infected individuals [14,30]. Unlike Egypt whose epidemic, drivers, and modes of exposure are relatively well understood [5,6,29,159,160], the nature of HCV transmission in this country remains poorly understood—this highlights the need for analytical epidemiologic studies in Pakistan to assess the specific modes of exposure and their relative role.

Another limitation of our study is that we used citation frequency to indicate the significance of the key associations and modes of exposures in the population, but citation frequency may not necessarily reflect the actual distribution of key associations and modes of exposures in the wider infected population—beyond the studied populations included in the present analysis. Furthermore, this delineation of key associations and modes of exposure may relate more to prevalence, rather than current incidence of infection. For example, blood safety and infection control appear to have improved markedly in recent years in multiple MENA countries [28,143,161]. Prevalent infections may therefore reflect decade’s old HCV exposures not representative of current exposures—the relative role of health care may have decreased but the role of injecting drug use may have increased. Further analytical epidemiologic studies, as well as viral hepatitis surveillance [162], are needed to determine current trends, particularly with a focus on incident infections.

About 400,000 new HCV infections are occurring in MENA every year [2], stressing the need to implement effective preventative strategies targeting the main clusters of exposure. Health care and injecting drug use appear to be the main drivers of the HCV epidemic in MENA, along with a smaller contribution from community-related exposures. Commitment to HCV prevention should be an integral component of HCV response to achieve HCV elimination by 2030. This commitment should entail expansion and quality assurance of blood and injection safety and infection control
programs, as well as harm reduction for people who inject drugs and in prisons.

Acknowledgments

Authors’ contributions: S.M. conducted extraction and analysis, and wrote the first draft of the article. L.J.A. conceived and led the design of the study, analyses, and drafting of the article. All authors contributed to the extraction of data and writing of the article.

This publication was made possible by NPRP grant number 9-040-3-008 from the Qatar National Research Fund (a member of Qatar Foundation). The findings achieved herein are solely the responsibility of the authors. The authors are also grateful for support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine in Qatar.

References

ranian Hepatitis C Virus Epidemiology Synthesis Project. 2017 (in press).
[5] Mohamud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epide-
[10] Chaabna K, Khouymjian SP, Abu-Raddad LJ. Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-
[18] A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013: The 64th Annual Meeting of the American Association for the Study of Liver Diseases November 1–5, 2013 • Washington DC• Special Reporting on • Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Ge-
notype 1 HCV Infection• Novel Interferon- and Ribavirin-Free Regimen Re-
sults in SVR12 Rates of Over 90% in HCV Genotype 1b Infections• Studies Confirm ORAL Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Geno-
type 1 Subpopulations• All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV• Fala-
deprevim Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in Difficult-to-Treat HCV Infection• Once Daily Sofosbuvir/


C้อnceptualization. For the purposes of this study, the conceptual phase involved the identification of the key issues surrounding the topic of concerted action for the prevention of HIV/AIDS in Asia and the Pacific region. The main objective was to define the scope of the project, to outline the major activities, and to set the overall goals and objectives. The conceptual framework was developed through a series of stakeholder consultations, workshops, and expert discussions. The framework was then refined and validated through a participatory process involving representatives from various sectors, including government, civil society, and the private sector. The conceptual framework was subsequently used to guide the design and implementation of the project, ensuring that it was aligned with the overarching goals of the initiative. The project aimed to enhance the capacity of countries in the region to develop and implement effective HIV/AIDS prevention programs, with a focus on promoting safe sexual practices, reducing unprotected sexual activity, and increasing access to HIV testing and counseling services. Through targeted interventions and strategic partnerships, the project sought to reach marginalized populations, including women, youth, and individuals living in remote or underserved areas. The project also focused on building the capacity of local organizations and networks to sustain and expand the implementation of effective prevention strategies in the long term. The project was led by the World Health Organization (WHO) and involved a range of international partners and stakeholders. It was funded through a combination of donor contributions and leveraging existing resources. The project spanned a period of several years, with implementation activities commencing in 2015 and concluding in 2020. The project outcomes were evaluated through a combination of process and impact assessments, with data collected from a diverse range of sources, including surveys, interviews, and case studies. The evaluation process aimed to provide robust evidence on the effectiveness of the project interventions and the extent to which the project's goals were achieved. The project’s achievements and lessons learned were disseminated through a range of platforms, including reports, publications, and presentations. These efforts aimed to inform future policy decisions and programming efforts in the region. The project's impact involved a significant increase in access to HIV testing and counseling services, particularly among underserved populations. There was also a notable improvement in the reach of HIV prevention campaigns and the adoption of safer sex practices among targeted groups. The project contributed to a more coordinated and comprehensive approach to HIV/AIDS prevention across the region, with enhanced capacity among local stakeholders to sustain and expand successful interventions. The project’s success was largely attributed to the strong partnerships and collaborative efforts between stakeholders, as well as the strategic alignment of the project with existing regional and international initiatives. Future efforts will continue to focus on addressing the gaps and challenges identified during the project, with a particular emphasis on scaling up effective interventions and ensuring their sustainability.


